Avalo Therapeutics
AVTX
52 hedge funds and large institutions have $113M invested in Avalo Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 5 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
5% less funds holding
Funds holding: 55 → 52 (-3)
11% less capital invested
Capital invested by funds: $127M → $113M (-$13.9M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 2 |
Two Sigma Advisers
New York
|
+$1.03M |
| 3 |
Two Sigma Investments
New York
|
+$864K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$699K |
| 5 |
BlackRock
New York
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.17M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$827K |
| 3 |
Renaissance Technologies
New York
|
-$744K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$526K |
| 5 |
Millennium Management
New York
|
-$368K |
AVTX Hedge Fund Activity: Q3 2020 in Review
52 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2020, worth a combined $113M — down 11% from $127M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of AVTX and 2 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 22 added.
The largest buyer was Vanguard Group, adding an estimated $1.87M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.17M sold.
- 52 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2020, down from 55 in Q2 2020.
- Funds reported $113M of Avalo Therapeutics stock for Q3 2020, down 11% quarter-over-quarter.
- 2 funds opened new Avalo Therapeutics positions in Q3 2020 and 5 closed out, a net change of -3 holders.
- The largest Avalo Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $1.87M added.
- The largest Avalo Therapeutics seller in Q3 2020 was Stonepine Capital Management, an estimated $1.17M sold.
Based on aggregated 13F filings for Q3 2020.